Evidence map›Paper›PMID 36618147›Full record

ArticleJournal of family medicine and primary care2022

Comparative study of clinical features and vaccination status in Omicron and non-Omicron infected patients during the third wave in Mumbai, India.

Apurva Takke, Mohini Zarekar, Vigneshwaran Muthuraman, Aditee Ashar, Kranti Patil, Anagha Badhavkar, Jayshil Trivedi, Naveen Khargekar, Manisha Madkaikar, Anindita Banerjee

Abstract read
In one paragraph

Article in Journal of family medicine and primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Apurva TakkeICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Mohini ZarekarICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Vigneshwaran MuthuramanICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Aditee AsharICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Kranti PatilICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Anagha BadhavkarICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Jayshil TrivediICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Naveen KhargekarICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Manisha MadkaikarICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.
Anindita BanerjeeICMR- National Institute of Immunohaematology (NIIH), KEM Hospital Campus, Mumbai, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: The Omicron variant-mediated COVID-19 wave is responsible for a global tsunami of cases. There is scarce data about the clinical and epidemiological characteristic analyses of the third wave. We present the data of COVID-19 patients from Mumbai region during the early third wave by taking S-gene target failure (SGTF) as a proxy for probable Omicron cases. Methods: We collected retrospective data of RT-PCR-confirmed (COVID-19) patients, and measured the proportion of possible Omicron cases by SGTF. We segregated and analyzed the clinical and lab data of patients with outcomes such as differing symptoms, vaccination coverage, previous infection, and travel history. We also performed a trend analysis of Mumbai's COVID-19 data before and during the third wave. Results: All patients had mild clinical symptoms while few were asymptomatic. Myalgia was more significantly present in SGTF/Omicron cases compared to non-SGTF/Delta patients. Out of the total 101 COVID-positive individuals, 94 individuals (93%) had taken two doses of COVID vaccine. Among these 94 individuals, 9 (8.9%) had been previously infected with COVID 19 in the first or second waves. 77.7% of the previously infected were now infected with Omicron variant and only 22.3% by a non-Omicron variant. Conclusion: Rapid rise and fall during the third wave in Mumbai was due to Omicron cases gradually replacing Delta. The overall milder clinical spectrum in both Omicron and Delta cases imply that vaccines might not be effective against re-infection but can attenuate disease severity and mortality, as evident by high coverage of vaccination in the country.

Indexed as

3rd waveclinical spectrumCOVID-19immunityOmicronvaccination

Identifiers

PMID36618147
PMCPMC9810849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.